Effect on Metabolic Parameters of Abilify in SPR

The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.

The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Inclusion Criteria:

• DSM-IV diagnosis with schizophrenia
• who signed an informed consent

Exclusion Criteria:

• comorbid with substance abuse or substance dependence
• pregnancy or lactation